immunocore-logo-2018
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
immunocore-logo-2018
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...
Logo.jpg
International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma
November 21, 2023 07:07 ET | Panavance Therapeutics Inc.
Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cellsBRAF-mutated melanoma accounts for approximately 50% of all melanomas BERWYN, PA, Nov. ...
Immuneering-logo (1).png
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023 16:05 ET | Immuneering Corporation
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
November 09, 2023 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
immunocore-logo-2018
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
image1 (1).png
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
November 06, 2023 10:12 ET | Evaxion Biotech
EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor...
Vaccinex logo
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023 09:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
October 30, 2023 16:30 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Emergen logo.png
Global Targeted Therapeutics Market Size to Reach USD 214.31 Billion in 2032 | Emergen Research
October 16, 2023 09:09 ET | Emergen Research
Vancouver, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Current Market Scenario (Market estimates) The global Targeted Therapeutics Market size was USD 93.75 Billion in 2020. Increasing prevalence of cancer,...